tiprankstipranks
Advertisement
Advertisement
Validating iBio’s Antibody Platform: Buy Rating Driven by IBIO-600’s Differentiated Obesity Profile and Long-Acting Myostatin Inhibition
PremiumRatingsValidating iBio’s Antibody Platform: Buy Rating Driven by IBIO-600’s Differentiated Obesity Profile and Long-Acting Myostatin Inhibition
2M ago
iBio Advances to Clinical Stage With IBIO-600 Trial
Premium
Company Announcements
iBio Advances to Clinical Stage With IBIO-600 Trial
2M ago
iBio receives regulatory clearance to initiate IBIO-600 trial in Australia
Premium
The Fly
iBio receives regulatory clearance to initiate IBIO-600 trial in Australia
2M ago
iBio to provide update on cardiopulmonary program
PremiumThe FlyiBio to provide update on cardiopulmonary program
3M ago
Buy Rating on iBio Driven by Promising IBIO-610 Obesity Data and Favorable Risk-Reward Profile
Premium
Ratings
Buy Rating on iBio Driven by Promising IBIO-610 Obesity Data and Favorable Risk-Reward Profile
3M ago
iBio Highlights IBIO-610 Obesity and Cardiometabolic Potential
Premium
Company Announcements
iBio Highlights IBIO-610 Obesity and Cardiometabolic Potential
3M ago
Biotech Alert: Searches spiking for these stocks today
PremiumThe FlyBiotech Alert: Searches spiking for these stocks today
3M ago
iBio: Differentiated Activin E Obesity Pipeline and Strengthened Balance Sheet Underpin Buy Rating
Premium
Ratings
iBio: Differentiated Activin E Obesity Pipeline and Strengthened Balance Sheet Underpin Buy Rating
4M ago
iBio reports Q2 EPS (9c), consensus (6c)
Premium
The Fly
iBio reports Q2 EPS (9c), consensus (6c)
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100